



October 24 - 25, 2024
Embassy of France,
4101 Reservoir Road, NW - Washington DC - 20007

SCIENTIFIC PROGRAM

CHAIRPERSONS

JAVED BUTLER (DALLAS, TX, USA)
STEPHEN HARRISON (SAN ANTONIO, TX, USA) (IN MEMORIAM)
VERONICA MILLER (BERKELEY, CA, USA)
ARUN SANYAL (RICHMOND, VA, USA)
FAIEZ ZANNAD (PARIS, FRA)



FACULTY

ACADEMY

1. Kushala W M Abeysekera (Bristol, GBR)
2. Alina Allen (Rochester, NY, USA)
3. Michael Böhm (Homburg/Saar, GER)
4. Jeroen Bax (Leiden, NED)
5. Javed Butler (Dallas, TX, USA)
6. Nicolas Girerd (Nancy, FRA)
7. Jim Januzzi (Boston, MA, USA)
8. Rohan Khera (New Haven, CT, USA)
9. Peter Juni (Oxford, GBR)
10. Aaron Mann (Piscataway, NJ, USA)
11. Cyrus Mehta (Boston, MA, USA)
12. Veronica Miller (Berkeley, CA, USA)
13. Chiadi Ndumele (Baltimore, MD, USA)
14. Mary Rinella (Chicago, IL, USA)
15. Michael Roden (Düsseldorf, GER)
16. Vlad Ratziu (Paris, FRA)
17. Arun Sanyal (Richmond, VA, USA)
18. Mohammad Siddiqui (Richmond, VA, USA)
19. Bart Staels (Lille, FRA)
20. Thomas Thum (Hannover, GER)
21. Muthiah Vaduganathan (Boston, USA)
22. Harriette Van Spall (Hamilton, ON, CAN)
23. Zobair M. Younossi (Falls Church, VA, USA)
24. Faiez Zannad (Paris, FRA)

PATIENTS

25. Michael Betel (Fatty Liver Alliance, CAN)
26. Henry Chang (Fatty Liver Foundation, USA)
27. Wayne Eskridge (Fatty Liver Foundation, USA)
28. Jeff McIntyre (Global Liver, USA)
29. Margaret Padilla (San Antonio, TX, USA)

REGULATORY

30. Lauren Dang (NIH, USA)
31. Charu Gandotra (FDA, USA)
32. Jay Hoofnagle (NIH, NIDDK, USA)
33. Alar Irs (EMA)
34. Mori Krantz (FDA, USA)
35. Mark Levenson (FDA, USA)
36. George Makar (FDA, USA)
37. William Sanders (FDA, USA)
38. Fred Senatore (FDA, USA)
39. John Sharretts (FDA, USA)
40. Raymond Soccio (FDA, USA)

41. Charmaine Stewart (FDA, USA)
42. Norman Stockbridge (FDA, USA)
43. Patrick Vrijlandt (EMA)

JOURNAL EDITORS

44. Flavia Geraldles (The Lancet, GBR)
45. Karen O'Leary (Nature Medicine, USA)
46. Patrick O'Malley (NEJM, USA)

INDUSTRY

47. Salvador Augustin (Boehringer Ingelheim, GER)
48. Scott Berry (Berry Consultants, Austin, USA)
49. Manu Chakravarthy (Carmot-Roche, USA)
50. Jerry Colca (Cirius, USA)
51. Michael Cooreman (Inventiva, FRA)
52. Andrea Dennis (Perspectum, GBR)
53. DeAunne Denmark (Somalogic, USA)
54. Nancy Dreyer (Dreyer Strategies, USA)
55. Michael Fried (TargetRWE, USA)
56. Jyothis George (Amgen)
57. Scott Harris (Altimmune, USA)
58. Mark Hartman (Lilly, USA)
59. Lars Johansson (Antaros, SWE)
60. Robert Lawatscheck (Bayer, GER)
61. Jennifer Linge (Amra, SWE)
62. Michelle Long (Novo Nordisk, DK)
63. Hank Mansbach (89 Bio, USA)
64. Peter Mesenbrink (Novartis, USA)
65. Erin Morgan (Ionis, USA)
66. David Nikodem (Metadeq, GBR)
67. Paul Nitschmann (Intercept Pharmaceuticals, USA)
68. Garg Pushka (Alnylam, USA)
69. James Rusnak (Pfizer, USA)
70. Rebecca Taub (Madrigal, USA)
71. Aldo Trylesinski (Metadeq, GBR)
72. Janet Wittes (Wittes LLC, USA)
73. Fred Yang (KBP, USA)
74. Ramy Younes (Boehringer, GER)

PAYER / ECONOMISTS / INVESTORS

75. Steven Farmer (CMS, USA)

**Thursday 24 October, 2024
8:30 -10:00**

**THE COMPETITIVE LANDSCAPE
CKM AND MASLD PIPELINE, TRIALS, APPROVALS, AND GUIDELINES
Chairpersons : Arun Sanyal (Richmond, VA, USA), Faiez Zannad (Paris, FRA)**

8.30-8.40

Major recent and ongoing CKM trials, approvals, and guidelines.
Faiez Zannad (Paris, FRA)

8.40-8.50

Major recent and ongoing MASLD/MASH trials, approvals, and guidelines.
Vlad Ratziu (Paris, FRA), Arun Sanyal (Richmond, VA, USA)

8.50-9.05 (5 min each)

What is in the CKM pipeline which has potential liver benefits
Robert Lawatscheck (Bayer, GER), Fred Yang (KBP, USA), Salvador Augustin (Boehringer, GER)

9.05-9.15

What is in the MASLD/MASH pipeline which has potential CKM benefits
Michael Cooreman (Inventiva, FRA), Jyothis George (Amgen, USA), Rebecca Taub (Madrigal, USA)

9.15-9.45

The MOSAIC Multi-Stakeholder Think Tank Moderated debate

**WEIGHING THE CURRENT DYNAMICS AND OPPORTUNITIES IN CKM AND MASLD
Chairpersons : Arun Sanyal (Richmond, VA, USA), Faiez Zannad (Paris, FRA)**

Panelists : all speakers

**09.45-10.00
Coffee break**

**Thursday 24 October, 2024
10:00 -11:00**

**SETTING THE STAGE FOR THE INTEGRATION OF CKM AND MASLD-NASH DISORDERS
Chairpersons : Ron Gansevoort (Groningen, NED), Vlad Ratziu (Paris, FRA)**

10.00-10.10

**The AHA Cardio-Kidney-Metabolism (CKM) confluence
Chiadi Ndumele (Baltimore, MD, USA)**

10.10-10.20

**CKM Overlap in Heart Failure trials
Muthiah Vaduganathan (Boston, USA)**

10.20-10.40

Defining the Cardio-Kidney-Liver-Metabolism (CKLM) paradigm. Intersecting, confluent, or consubstantial?

10.20-10.30

**Insight from epidemiology
Zobair M. Younossi (Falls Church, VA, USA)**

10.30-10.40

**Insight from pathophysiology
Bart Staels (Lille, FRA)**

10.40-11.00

The MOSAIC Multi-Stakeholder Think Tank Moderated debate

AGREEING ON THE SIZE AND NATURE OF THE INTERSECTIONS.

Chairpersons : Ron Gansevoort (Groningen, NED), Vlad Ratziu (Paris, FRA)

Panelists : all speakers

Thursday 24 October, 2024

HOW TO BEST CHARACTERIZE THE CARDIO-KIDNEY-LIVER-METABOLISM (CKLM) INTERSECTIONS.

Part 1. 11.00 – 12.00

AVAILABLE CLINICAL DATA IN EXISTING RESPECTIVE CKM AND MASLD COHORTS AND TRIALS
Chairpersons : Michael Böhm (Homburg/Saar, GER), Zobair M. Younossi (Falls Church, VA, USA)

MASLD/MASH data in CKM trials

11.00 – 11.10

Cardiology trials

Michael Böhm (Homburg/Saar, GER)

11.10 – 11.20

Nephrology trials

Ron Gansevoort (Groningen, NED)

CKM data in MASLD/MASH trials

11.20 – 11.30

CKM biomarker signatures/phenotypes in MASLD/MASH trials

Michael Cooreman (Inventiva, FRA)

11.30 – 11.40

Liver biomarker signatures/phenotypes in CKM trials

Michael Roden (Düsseldorf, GER)

11.40-12.00

The MOSAIC Multi-Stakeholder Think Tank Moderated debate

WHAT DO WE ALREADY KNOW ABOUT EACH OTHER ?

Chairpersons : Michael Böhm (Homburg/Saar, GER), Zobair M. Younossi (Falls Church, VA, USA)

Panelists : all speakers

12.00-13.00

Lunch

Thursday 24 October, 2024

HOW TO BEST CHARACTERIZE THE CARDIO-KIDNEY-LIVER-METABOLISM (CKLM) INTERSECTIONS.

Part 2. 13.00-14.30

HOW TO HARVEST EXISTING TRIALS' DATA AND BIOBANKS?

Chairpersons : Veronica Miller (Berkeley, CA, USA), Naveed Sattar (Glasgow, GBR)

13.00-13.10

**Opportunities for cross-disorders investigations. The Liver Forum Collaboratory
Veronica Miller (Berkeley, CA, USA)**

13.10-13.25

**Industry willingness to share completed trials resources (5 min each)
Salvador Augustin (Boehringer Ingelheim, GER), Hank Mansbach (89 Bio, USA), TBD (Novonordisk, DEN)**

13.25-13.35

**Liver risk stratification
Kushala W M Abeysekera (Bristol, GBR)**

13.35-13.45

**Metabolic risk stratification
Naveed Sattar (Glasgow, GBR)**

13.45-13.55

**How to use existing databases and biobanks for CKLM druggable biotargets discovery?
Thomas Thum (Hannover, GER)**

13.55-14.05

**The potential of unbiased phenomapping using AI and datamining of existing databases.
Rohan Khera (New Haven, CT, USA)**

14.05-14.30

**Regulatory panel viewpoints
Mori Krantz (FDA, USA), George Makar (FDA, USA), John Sharretts (FDA, USA), Raymond Soccio (FDA, USA), Charmaine Stewart (FDA, USA), Norman Stockbridge (FDA, USA), Alar Irs (EMA)**

14.30-15.00

The MOSAIC Multi-Stakeholder Think Tank Moderated debate

HARVESTING EXISTING TRIALS' DATA AND BIOBANKS.

HOW TO OPERATIONALISE COLLABORATION?

Chairpersons : Veronica Miller (Berkeley, CA, USA), Naveed Sattar (Glasgow, GBR)

Panelists : all speakers

15.00-15.30

Coffee Break

**Thursday 24 October, 2024
15.30-17.40**

**EMBEDDING CKM SUB-STUDIES IN MASLD/MASH TRIALS AND MASLD/MASH
SUB-STUDIES IN CKM TRIALS**

Chairpersons : Jim Januzzi (Boston, MA, USA), Mohammad Siddiqui (Richmond, VA, USA)

15.30-15.50

Clinical sub-studies

Nicolas Girerd (Nancy, FRA)

Mohammad Siddiqui (Richmond, VA, USA)

15.50-16.10

Biomarker sub-studies

Arun Sanyal (Richmond, VA, USA)

Jim Januzzi (Boston, MA, USA)

16.10-16.30

Bioimaging sub-studies

Jeroen Bax (Leiden, NED)

Alina Allen (Rochester, NY, USA)

16.30-16.50

Industry viewpoints (5 min each)

Pharma industry

Michelle Long (Novo Nordisk, DEN)

Biomarker industry

TBD

Imaging industry

Lars Johansson (Antaros, SWE), Andrea Dennis (Perspectum, GBR),

16.50-17.10

Regulatory panel viewpoints

**George Makar (FDA, USA), William Sanders (FDA, USA), John Sharretts (FDA, USA), Raymond Soccio (FDA, USA),
Charmaine Stewart (FDA, USA), Norman Stockbridge (FDA, USA), Alar Irs (EMA)**

17.10-17.40

The MOSAIC Multi-Stakeholder Think Tank Moderated debate

PRACTICAL FEASIBILITY OF ANCILLARY STUDIES

Chairpersons : Jim Januzzi (Boston, MA, USA), Mohammad Siddiqui (Richmond, VA, USA)

**Panelists : all speakers and Salvador Augustin (Boehringer Ingelheim, GER), DeAunne Denmark (Somalogic, USA),
Jennifer Linge (Amra, SWE)**

FIRST DAY ADJOURN

18.30

NETWORKING, DINNER AND RECEPTION

**Friday 25 October, 2024
8:00-09:20**

HOW REAL-WORLD DATA MAY HELP?

Chairpersons : Veronica Miller (Berkeley, CA, USA), Harriette Van Spall (Hamilton, ON, CAN)

8.00-8.10

**The Causal Road Map
Lauren Dang (NIH, USA)**

8.10-8.20

**How to construct a «RWD» cohort to contribute as RWEvidence (claims, EHRs, etc),
Nancy Dreyer (Dreyer Strategies, USA)**

8.20-8.30

**Case studies (5 min each)
Michael Fried (TargetRWE, USA)
Paul Nitschmann (Intercept Pharmaceuticals, USA)**

8.30-8.40

**How would a shared placebo cohort work as supplemental control
Veronica Miller (Berkeley, CA, USA)**

8.40-8.50

**Developing a culture of data sharing. The clinical research data sharing alliance experience
Aaron Mann (Piscataway, NJ, USA)**

8.50-9.20

The MOSAIC Multi-Stakeholder Think Tank Moderated debate

BUILDING A COMMON RWD AGENDA

Chairpersons : Veronica Miller (Berkeley, CA, USA), Harriette Van Spall (Hamilton, ON, CAN)

Panelists : all speakers

**09.20-09.40
Coffee break**

**Friday 25 October, 2024
9:40-13:30**

**INTEGRATED MULTI-ORGAN CKLM TRIALS.
DEVELOPING A TEMPLATE PROTOCOL**

Part 1. 9.40-11.30

**DEFINING THE IDEAL INTEGRATED TARGET PATIENT POPULATIONS AND THE RIGHT ENDPOINTS
Chairpersons : Javed Butler (Dallas, TX, USA), Arun Sanyal (Richmond, VA, USA)**

9.40-9.50

**Enriching CKM trial populations for liver outcomes
Mary Rinella (Chicago, IL, USA)**

9.50-10.00

**Enriching MASLD trial populations for CK outcomes
Javed Butler (Dallas, TX, USA)**

10.00-10.10

**Integrated CKLM patient populations. What should be a typical set of inclusion/exclusion criteria?
TBD**

10.10-10.20

**Addressing diversity and inclusiveness issues
Harriette Van Spall (Hamilton, ON, CAN)**

10.20-10.30

**What does it take for progressing from liver surrogate endpoints to MALE and to liver hard outcomes?
Arun Sanyal (Richmond, VA, USA)**

10.30-10.40

**The value of composite endpoints integrating CKM components with Liver components
Faiez Zannad (Paris, FRA)**

10.40-10.50

**Statistician viewpoint
Janet Wittes (Wittes LLC, USA)**

10.50- 11.10

**Regulatory panel viewpoints
George Makar (FDA, USA), Fred Signore (FDA, USA) John Sharretts (FDA, USA), Raymond Soccio (FDA, USA), Charmaine Stewart (FDA, USA), Norman Stockbridge (FDA, USA), Patrick Vrijlandt (EMA)**

11.10-11.40

The MOSAIC Multi-Stakeholder Think Tank Moderated debate

DEVELOPING A TEMPLATE PROTOCOL

**Part 1. Defining the ideal integrated target patient populations and the right endpoints
Chairpersons : Javed Butler (Dallas, TX, USA), Arun Sanyal (Richmond, VA, USA)**

Panelists : all speakers

**Friday 25 October, 2024
9:40-13:30**

**INTEGRATED MULTI-ORGAN CKLM TRIALS.
DEVELOPING A TEMPLATE PROTOCOL**

Part 2. 11.40-13.30

**DEFINING THE IDEAL INTEGRATED TRIAL DESIGN
CHAIRPERSONS : JANET WITTES (WITTES LLC, USA), TBD**

11.40-11.50

The value of master protocols, platform, umbrella and basket design trials
Scott Berry (Berry Consultants, Austin, USA)

11.50-12.00

Case study for platform study in MASH
Peter Mesenbrink (Novartis, USA)

12.00-12.10

The value of pragmatic design and registry randomized trials
Peter Juni (Oxford, GBR)

12.10-12.20

Adaptive design and interim analyses
Cyrus Mehta (Boston, MA, USA)

12.20-12.25

Industry viewpoint
Salvador Augustin (Boehringer Ingelheim, GER)

12.25-12.30

Regulatory statistical viewpoints
Mark Levenson (FDA, USA)

12.30-12.50

Regulatory panel viewpoints
Charu Gandotra (FDA, USA), George Makar (FDA, USA), John Sharretts (FDA, USA), Raymond Soccio (FDA, USA),
Charmaine Stewart (FDA, USA), Norman Stockbridge (FDA, USA), Patrick Vrijlandt (EMA)

12.50-13.30

The MOSAIC Multi-Stakeholder Think Tank Moderated debate

DEVELOPING A TEMPLATE PROTOCOL

**Part 2. Defining the ideal integrated trial design
Chairpersons : Janet Wittes (Wittes LLC, USA), TBD**

Panelists : all speakers

**13.30-14.30
Lunch**

**Friday 25 October, 2024
14:30-15:10**

**IS SEEKING CKLM MULTI-ORGAN COMBINATORIAL DRUGS ATTRACTIVE?
Chairpersons : Flavia Geraldes (The Lancet, GBR), Karen O'Leary (Nature Medicine, USA)**

14.30-14.50 (5 mins each)

Publishing manuscripts integrating cardiovascular, Kidney, metabolism and liver data
Flavia Geraldes (The Lancet, GBR), Karen O'Leary (Nature Medicine, USA), Patrick O'Malley (NEJM, USA)

14.50-15.00 (5 mins each)

Coverage of combinatorial medications with multi-organ indications.
Steven Farmer (CMS, USA)
TBD (NICE)

15.00-15.10

Funding trials seeking multiple approvals, targeting multi-organ combinatorial indications
Jay Hoofnagle (NIH, NIDDK, USA)

15.10-16.30

The MOSAIC Multi-Stakeholder Think Tank Moderated debate

FUTURE STEPS AND ACTIONABLE SOLUTIONS

MOSAIC Chairpersons : Javed Butler (Dallas, TX, USA), Veronica Miller (Berkeley, CA, USA), Arun Sanyal (Richmond, VA, USA), Faiez Zannad (Paris, FRA)

1. How do we practically make liver trials do CKM phenotyping and vice versa.
2. How do we practically make liver trials collect CKM endpoints and vice versa.
3. What could be a typical CKLM integrated trial design?

Patients Forum

Michael Betel (Fatty Liver Alliance, CAN), Henry Chang (Fatty Liver Foundation, USA), Wayne Eskridge (Fatty Liver Foundation, USA), Jeff McIntyre (Global Liver, USA), Margaret Padilla (San Antonio, TX, USA)

Panelists: all faculty

16.30 ADJOURN